All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

  TRANSLATE

The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Are you planning a phase II study of glasdegib in refractory sclerotic chronic GvHD?

Featured:

Eduardo Rodríguez ArbolíEduardo Rodríguez Arbolí

Jun 18, 2021


During the EHA2021 Virtual Congress, the GvHD Hub spoke with Eduardo Rodriguez Arboli, University of Seville, Seville, ES. We asked, Are you planning a phase II study of glasdegib in refractory sclerotic chronic GvHD?

Are you planning a phase II study of glasdegib in refractory sclerotic chronic GvHD?

In this video, Arboli reports on the results of a phase I study evaluating the safety and efficacy of glasdegib in patients with sclerotic chronic GvHD. He discusses tolerability, dosing, calcium channel blockers for muscle cramps, and the ongoing phase II study.